
Solid Biosciences Inc.: updates and filings
Price
$6.25
November 20, 2026Market cap $944M
What Ploutos Investor adds for Solid Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2025next Feb 3, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
August 2026
March 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Aug 14, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Other material eventsForm8-K
- Aug 6, 2026Shelf registration for future offeringsFormS-3ASR
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 24, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 10, 2026Shareholder voteForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Apr 10, 2026Preliminary proxy statementFormPRE 14A
- Apr 10, 2026Officer or director changeForm8-K
- Mar 31, 2026FilingFormEFFECT
- Mar 31, 2026FilingFormEFFECT
- Mar 27, 2026Correspondence with the SECFormCORRESP
- Mar 27, 2026Correspondence with the SECFormCORRESP
- Mar 24, 2026Letter from the SECFormUPLOAD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Aug 14, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 8-K | Other material events | Document |
| Aug 6, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 24, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 10, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 10, 2026 | 8-K | Officer or director change | Document |
| Mar 31, 2026 | EFFECT | Filing | Document |
| Mar 31, 2026 | EFFECT | Filing | Document |
| Mar 27, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 27, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 24, 2026 | UPLOAD | Letter from the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 4, 2017.
The full analysis
What do Solid Biosciences's filings show?
The filings are where every one of Solid Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.